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EVIDENCE BASED NEURO-ONCOLOGY
MR perfusion imaging, techniques and role in differentiating radiation necrosis
and tumor recurrence
Raima Zakaria, Fatima Mubarak, Muhammad Shahzad Shamim

Abstract

Introduction

High grade brain tumours are treated with surgery,
chemotherapy and radiation therapy and despite such
aggressive treatment, can recur in a short span of time.
MRI scan has been the conventional diagnostic modality
to diagnose recurrence, although at times it becomes
difficult for the neuroradiologists to differentiate
between tumour recurrence and radiation necrosis.
Herein lies the emergent need to explore the efficacy of
functional imaging to assist in this diagnostic
challenge.Recent studies have sought to do so with
promising implications, which we have attempted to
summarize in this review.

Despite aggressive treatmenrt regimes for high grade
brain tumours, recurrence remains inevitable.1 For a
considerable amount of time, conventional contrast
enhanced MR imaging has been the mainstay of
assessing post treatment tumour recurrence, especially
in CNS neoplasms.The usual indicators of a recurrent
tumour on follow up MRI include progressive
enlargement of lesion, causing mass effect and
infiltration of corpus callosum; whereas the
enhancement pattern following a Swiss cheese or
spreading wavefront pattern is more indicative of
radiation necrosis.2 Over the years considerable overlap
between these two types has been observed which has
prompted new research efforts into investigating
advanced non-invasive imaging methods measuring
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Figure : Enhancing right frontal lobe lesion with perfusion showing raised CBV along medial margins and center representing viable tumour, supporting a diagnosis of recurrence.
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physiological tumour properties.3 Novel modern day
research centers on bringing forth the capabilities of MR
perfusion in exploiting the functional differences at the
cellular level between recurrent or progressive tumour
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growth from treatment-induced necrosis after radiation
therapy.These include increased cell proliferation with
neo-angiogenesis in case of tumour; and liquefactive
necrosis, vascular hyalinization and endothelial damage
in case of radiation induced changes.4 The observed
clinical symptoms vary from none to significant
neurological deficit predominantly affecting the white
matter. Vermaet al.,5 reported an incidence of 3–24% for
radiation necrosis, showing a direct correlation with the
dose of radiation, duration and volume of targeted brain
parenchyma.

Technique
In perfusion scanning, successive images are obtained
during the first pass of contrast. There are two methods
of obtaining perfusion sequences namely dynamic
susceptibility-weighted contrast-enhanced (DSC) and
dynamic contrast-enhanced (DCE) imaging. In DSC-MRI,
the susceptibility effect of contrast causes a T2 signal
drop in DSC-MR thus allowing measurement of
haemodynamic parameters: relative cerebral blood
volume (rCBV), relative peak height (rPH), and
percentage of signal-intensity recovery (PSR). Higher
rCBV indicates highly permeable blood vessels as in the
case of tumour neo-angiogenesis whereas lower values
stipulate treatment necrosis reducing blood flow.5 CBV
data is compared with the contralateral side for
normalization hence the term relative.6 In DCE-MRI,
rapid sequence T2 imaging is used to measure signal
intensities of contrast bolus which reflects lesion
perfusion, permeability and extracellular volume.
However very few precedents are found in literature that
show compelling results in application of DCE-MRI to
the question of tumour recurrence versus radiation
necrosis.5

Review of Evidence
Prager et al.7, conducted perfusion analysis in post
treatment enhancing lesions for patients with primary
high grade gliomas. They reported lower rCBV values in
treatment related changes, rCBV lesion (P = 0.003) and
rCBVROI (region of interest) (P = 0.011). An optimized
rCBV lesion threshold of ≥1.27 had 86.5% sensitivity and
83.3% specificity with AUC (area under curve) of 0.863
for the diagnosis of recurrence.Barajas et al.8, performed
a retrospective review of 27 patients that underwent
gamma knife radiosurgery for metastatic lesions of the
brain.Upon follow up patients that presented with
enhancing lesions on conventional imaging were
selected and ROI were drawn around the entire contrastenhancing region.Their observations stipulated lower
rCBV (P <0.01) in lesions with necrosis. A cutoff rCBV
value of 1.52 in enhancing lesions withstood cross-
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validation with a sensitivity of 91.30% and specificity of
72.73 for tumour recurrence.
Sugahara et al.9, were amongst the initial investigators
to pave the way for future research efforts that may
solidify the role of MR perfusion in this area. In their
landmark paper they reported higher normalized ratios
of rCBV in the tumour recurrence group compared to
those of the non-neoplastic group. The differences
between the two groups reached statistical significance,
P value 5.03 and 0.02, respectively. A sensitivity of 50%
and a specificity of 90% for perfusion-sensitive contrastenhanced MR imaging at a cutoff value of 1.0 for
normalized rCBV ratios was reported.They also
presented a detailed overview of overlap in normalized
rCBV ratios between the two groups. According to them,
the factors that may have affected the ratios include
coexisting neoplastic and necrotic tissue, the affected
vessels in irradiated tissue being prone to vascular
phenomena such as formation of aneurysmal or
telangiectatic collaterals resulting in larger rCBV ratios,
and finally post radiation petechial haemorrhages that
reduce the rCBV when occurring in areas of tumour
recurrence.Young et al.10,also reported that patients in
their study group comprising of treated glioblastoma
with progressive disease demonstrated significantly
higher median rCBV with P=0.009.
In a recently published meta-analysis, Chuang MT et
al.11, reviewed 13 articles that encompassed a total of
397 patients not restricted by tumour type as these
included primary plus metastatic lesions providing a
bigger picture to comprehend the versatile role of MR
perfusion in lesion characterization.They concluded that
average rCBV was significantly higher in tumour
recurrence compared with radiation injury (all P <
0.05).Bobek-Billewicz et al.12, compared the efficacy of
MR perfusion over MR spectroscopy in differentiating
true recurrence from radiation injury. They made
observations that show statistically significant
difference in terms of rCBV between tumour recurrence
and radiation injury group (rCBVmax p < 0.001,
rCBVmean p < 0.005) with mean rCBV being more
plausible as a differing factor than max rCBV.

Conclusion:
In the light of available evidence as briefed in our review,
it would be safe to conclude that functional MR imaging
has far progressed over the years as a potential noninvasive tool for differentiating between tumour
recurrence and radionecrosis.MR perfusion has been
consistently reported as a promising adjunct for the
distinction between recurrent tumour and radiation
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